Jinqiu Zhang, Xuejing Liu, Arpita Datta, Kunde Govindarajan, Wai Leong Tam, Jianyong Han, Joshy George, Christopher Wong, Kalpana Ramnarayanan, Tze Yoong Phua, Wan Yee Leong, Yang Sun Chan, Nallasivam Palanisamy, Edison Tak-Bun Liu, Krishna Murthy Karuturi, Bing Lim, Lance David Miller
J Clin Invest.
2009;
119(8):2171–2183
doi:10.1172/JCI37622
This article Copyright © 2009, The American Society for Clinical Investigation
Abstract
|
Full text
|
PDF
|
Supplemental material
A
ggressive forms of cancer are often defined by recurrent chromosomal alterations, yet in most cases, the causal or contributing genetic components remain poorly understood. Here, we utilized microarray informatics to identify candidate oncogenes potentially contributing to aggressive breast cancer behavior. We identified the Rab-coupling protein RCP (also known as RAB11FIP1), which is located at a chromosomal region frequently amplified in breast cancer (8p11–12) as a potential candidate. Overexpression of RCP in MCF10A normal human mammary epithelial cells resulted in acquisition of tumorigenic properties such as loss of contact inhibition, growth-factor independence, and anchorage-independent growth. Conversely, knockdown of RCP in human breast cancer cell lines inhibited colony formation, invasion, and migration in vitro and markedly reduced tumor formation and metastasis in mouse xenograft models. Overexpression of RCP enhanced ERK phosphorylation and increased Ras activation in vitro. As these results indicate that RCP is a multifunctional gene frequently amplified in breast cancer that encodes a protein with Ras-activating function, we suggest it has potential importance as a therapeutic target. Furthermore, these studies provide new insight into the emerging role of the Rab family of small G proteins and their interacting partners in carcinogenesis.
